Clinical trial
Immunotoxin Therapy in Treating Children With Progressive or Recurrent…
NCT00052624 · Xenova Biomedix, Industry · Unknown status
Key facts
| NCT number | NCT00052624 |
|---|---|
| Title | Immunotoxin Therapy in Treating Children With Progressive or Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma |
| Official title | A Phase I Multicenter Trial Of Intratumoral/Interstitial Therapy With HN66000, NC66000 (TransMID) In Patients Between 5 and 18 Years Of Age With Progressive Or Recurrent Glioblastoma Multiforme Or Anaplastic Astrocytoma |
| Lead sponsor | Xenova Biomedix, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological |
| Interventions | transferrin-CRM107 |
| Start date | Jul 1, 2002 |
| First posted | Jan 27, 2003 |
| Last update posted | May 15, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: